AdBio partners
Venture capitalParis · Pre-Seed–Series A · 3 people tracked
Find your way into AdBio partners
513 people in our graph share verified history with the AdBio partners team — schools, employers, funds. One of them is your warm intro.
Investment thesis
AdBio Partners invests in and develops early-stage life sciences startups across Europe, targeting the most promising therapeutic innovations across various therapeutic areas. Combining business, scientific, and financial expertise, the firm positions itself as both entrepreneurs and investors, sourcing breakthrough medical discoveries and building sustainable startups alongside scientific founders and academic institutions. It works with leading research institutions and technology transfer offices, supported by a network of scientific and industrial partners and international VC syndicates.
Source: firm website, verified Aug 3, 2026.
Team · 3 people
from the firm's website & public directories
Founder mafia
2 people who came through AdBio partners went on to found or lead other companies.
What they invest in
from 18 of 40 portfolio companiesBiotech ×17Healthtech ×11Medical Devices ×10Deep Tech ×7Digital Health ×5Longevity ×2AI & Machine Learning ×1Gaming ×1
HQs:France×7Belgium×1Spain×1United States×1
Investments · 40 tracked
founders shown can be your intro path
AndzonBio operates a suite of thematic "pipeline builder" studios that accelerate the industrial development of academic life sciences projects into biotech companies, focusing on specific therapeutic areas such as cardiovascular/renal/metabolic disorders and neurological disorders.
BiotechDeep TechHealthtech
Andzonbio1 is a biotech start-up developing therapeutics and building a pipeline, supported by public and private funding sources in France.
BiotechHealthtechMedical DevicesParis, FR
Vincent Bischoff(Chief Executive Officer)inSébastien Bolze(Chief Scientific Officer)
DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes.
BiotechDeep TechDigital HealthHealthtechMarseille, FR
Benjamin Charles(Co-Founder & CEO)inPatrick Collombat(Co-Founder & Scientific Advisor)inJean-Pascal Tranié(Co-Founder)in
Co-investorsRoche Venture FundBoehringer Ingelheim Venture FundSunstone CapitalJDRF T1D Fund
Agomab is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory and fibrotic diseases with high unmet medical need.
BiotechHealthtechMedical DevicesAntwerp, BE
Tim Knotnerus(Chief Executive Officer)in
Co-investorsEQT Life SciencesAndera PartnersAsabys PartnersCanaan PartnersPontifax Venture CapitalV-Bio Ventures+1 more
AndzonBio2 develops neuroinflammation therapies targeting STING and lipid peroxidation pathways, aiming to intervene in central nervous system diseases through translational research and drug development.
BiotechDeep TechDigital HealthHealthtech
Loic Lhuillier(Co-founder)in
Arthex Biotech develops antisense RNA compounds to treat diseases with unmet medical needs.
AI & Machine LearningBiotechMedical Devices
Beatriz Llamusí(Chief Scientific Officer & Co-Founder)in
Co-investorsBpifranceColumbus Venture PartnersHadean VenturesSound BioventuresInvivo Capital Partners
Astraveus develops the Lakhesys Benchtop Cell Factory, a microfluidic-based bioprocessing platform for scaling cell and gene therapy manufacturing with improved quality and cost efficiency.
BiotechDeep TechMedical DevicesParis, FR
Jérémie Laurent(Chief Executive Officer)
Co-investorsM Ventures
Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS.
BiotechMedical Devices
Co-investorsJeito CapitalNovo HoldingsPMVV-Bio VenturesAsabys PartnersNewton Biocapital
Cephagenix is a biotech company working on identifying and developing new treatments for migraine.
BiotechHealthtechParis, FR
EVL Bio is developing a selective anti-FGFR4 monoclonal antibody therapy to treat left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD).
BiotechDigital HealthLongevity
Robert Kirmeier(Founder)inWenzel von der Heydte(Founder)in
Co-investorsKurma Partners
KIJI Tx develops gene-engineered iPSC-derived MSC cell therapies for treating a broad range of inflammatory diseases, with a lead product using IL10 and CXCR4 transduction.
BiotechHealthtechMedical Devices
Juan Bueren(Scientific Founder)Rosa Yanez(Scientific Founder)Maria Fernandez(Scientific Founder; Product Manager)Begona Diez(Scientific Founder)Mercedes Lopez(Scientific Founder)Miguel Forte(CEO)in
Orikine Bio develops engineered cytokines called Foldikines™ to reprogram immune responses for treating autoimmune and inflammatory diseases.
BiotechDeep TechHealthtechMedical DevicesBarcelona, ES
Ariadna Montero(Scientific Founder, Head of Innovation Management & Corp. Comm.)inAlejo Chorny(Co-founder & Former-CEO)inProf. Luis Serrano(Scientific Founder, Advisor)Dr. Javier Delgado(Scientific Founder, Advisor)Christian Pangratz(CEO & Board Director)in
BoardLarry Edwards(Chairman of the Board)
Co-investorsAsabys Partners
The page promotes an online gambling/betting brand ("regalbet") presented as a digital gaming platform, using SEO-style marketing text targeting players in large cities.
Gaming
SparingVision develops neuroprotective gene therapies for rare genetic diseases affecting the eye and nervous system.
BiotechDeep TechDigital HealthMedical Devices
Co-investorsJeito CapitalYsios Capital
Tenpoint Therapeutics develops treatments for age-related ophthalmic conditions, with an initial focus on presbyopia care for the aging eye.
BiotechDigital HealthHealthtechLongevityMedical DevicesWarren, US
HENRIC BJARKE(Chief Executive Officer)in
Co-investorsF-Prime CapitalSofinnova Partners
Thabor Therapeutics is an INSERM spin-off developing a first-in-class therapeutic antibody targeting AGR2 for treating inflammatory mucosal diseases.
BiotechMedical DevicesRennes, FR
Eric Chevet(Head of U1242 unit)Xavier Treton(Gastroenterologist, Co-founder Institut des MICI)in
Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases.
BiotechDeep TechHealthtechParis, FR
Co-investorsAdvent Life SciencesBioqube VenturesBpifrancePureos Bioventures
Urania Therapeutics develops treatments for genetic diseases and cancers caused by nonsense mutations, targeting monogenic diseases in which a single gene defect impairs production of a functional protein.
BiotechHealthtech
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Alderaan Biotechnology’s websiteAndzonBioAndzonBio1AndzonBio2Anoat TherapeuticsARTHEx BiotechAstraveusCalida TherapeuticsCephagenixDepth ChargeDiogenXEvlabioIntegra TherapeuticsKalsiomKiji TherapeuticsRibonexusSparingVisionThabor TherapeuticsTridek-OneUnivercells’s websiteUrania TherapeuticsYukin Therapeutics
Portfolio news
latest coverage across their companiesTenpoint Therapeutics · ophthalmologytimes.com · Aug 30, 2026
Agomab Therapeutics · investing.com · Aug 10, 2026
Frequently asked questions
- How many investments has AdBio partners made?
- AdBio partners has 40 tracked investments.
- What stage does AdBio partners invest at?
- AdBio partners invests at the Pre-Seed, Seed, Series A stages.
- What sectors does AdBio partners focus on?
- AdBio partners focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is AdBio partners located?
- AdBio partners is headquartered in Paris, FR.
- Who does AdBio partners co-invest with?
- AdBio partners most often shares deals with Jeito Capital, Asabys Partners, Invivo Capital Partners, among 21 tracked co-investors.
Similar investors
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
InnoCom Bio Equities manages life science special purpose vehicles, offering investors a diversified portfolio of innovative life sciences technologies and providing seed capital to innovators and founders.
Medical Excellence Capital (MEC) is a venture firm focused on precision health and life sciences, pairing investment professionals and operators with a proprietary national medical network platform.
Mission BioCapital provides early-stage capital and shared lab space to life science entrepreneurs, supporting companies from idea through clinic and exit.